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Abstract
Cirrhotic cardiomyopathy (CCMP) is a functional disorder characterized by electro-
physiologic disturbances and diastolic  and/or systolic  dysfunction in patients with
chronic  liver  disease,  especially  those  with  ascites  and  portal  hypertension.  This
disorder is a well-defined entity in adults, but pediatric data are limited. Clinical and
laboratory findings are generally latent. The diagnostic criteria are prolonged QT on
electrocardiography due to metabolic and extrahepatic causes, in addition to some
abnormal echocardiography findings. If echocardiographic findings are normal and
only  specific  prolonged QT is  present,  this  disorder  is  named as  “latent  CCMP”;
otherwise, it is “manifest CCMP.” This disorder is important because it may lead to
problems such as cardiac failure and dysrhythmia before or after liver transplantation.
Moreover, it may worsen the prognosis.
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1. Introduction
Portal hypertension (PHT) is an important disorder that increases morbidity and mortality
rates. Many hemodynamic changes related to PHT occur in the human body. The majority of
these  changes  are  associated  with  hyperdynamic  circulation,  which  is  characterized  by
elevated heart rate and cardiac output accompanied by vasodilatation in the splanchnic area
and  systemic  circulation  and  decreased  systemic  vascular  resistance  [1–9].  Moreover,
disturbances of the autonomic nerve system and baroreceptors and the increased arterial
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compliance in patients with cirrhosis aggravate the condition [10–12]. Hemodynamic changes
that occur in portal hypertension are shown in Table 1.
Cardiovascular disorders associated with cirrhosis were first defined in alcoholic cirrhotic
patients, in 1953 by Kowalski and Abelmann, but for many years, it was thought that these
disorders were associated with chronic alcohol intake [10–12]. Similar disturbances were
described in patients with cirrhosis who had hemochromatosis in some later research, but this
time the changes were associated with hemochromatosis [13]. Consequently, cirrhotic cardio‐
myopathy was not known in those years.
Systemic circulation
Plasma volume ↑
Total blood volume ↑
Noncentral blood volume ↑
Central arterial blood volume → ↓ (↑)
Cardiac flow (→) ↑
Arterial blood tension → ↓
Heart rate ↑
Systemic vascular resistance ↓
Heart
Left atrial volume ↑
Left ventricle volume → (↓)
Right atrial volume → ↑ ↓
Right ventricle volume → ↑ ↓
Right atrial tension → ↑
Right ventricle end‐diastole tension →
Pulmonary arterial tension → ↑
Pulmonary capillary wedge tension →
Left ventricle end‐diastole tension →
Pulmonary circulation
Pulmonary blood flow ↑ Pulmonary vascular resistance ↓ (↑)
Renal circulation
Renal blood flow ↓ Renal vascular resistance ↑
Cerebral circulation
Cerebral blood flow ↓ →
Skin, muscular, and skeletal circulation
Skin blood flow → ↑ Muscular and skeletal circulation → ↑ ↓
↑, increased; ↓, decreased; →, not changed
Table 1. The hemodynamic changes due to cirrhotic portal hypertension [6].
Caremelo et al. first described cirrhotic cardiomyopathy in 1986. The authors demonstrated
cardiac function disturbances due to cirrhosis in an experimental rat model and suggested the
cirrhotic cardiomyopathy hypothesis. Their hypothesis was supported by subsequent research,
and cardiac disorders due to cirrhosis and portal hypertension were named “cirrhotic cardio‐
myopathy” in 1989 [1–12, 14]. Although the name “hepatocardiac syndrome” was proposed by
some authors instead of “cirrhotic cardiomyopathy,” this term was not accepted [14].
2. Definition
Cirrhotic cardiomyopathy (CCMP) is defined as a functional disorder characterized by
electrophysiologic disturbances and diastolic and/or systolic dysfunction in patients with
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cirrhotic PHT. Even though similar hemodynamic changes have been defined in long‐term
non‐cirrhotic PHT, the development of CCMP in such patients has not been reported. There‐
fore, this term is usually used for patients with cirrhosis [10, 15–18].
3. Pathogenesis
In general, arterial vasodilatation, central hypovolemia, and hyperdynamic circulation which
occur as a result of cirrhosis and portal hypertension lead to the development of CCMP
together with hepatorenal syndrome and hepatopulmonary syndrome (Figure 1) [11, 19–23].
Effects of vasoactive agents are very important in pathogenesis of CCMP. Experimentally, some
changes were defined in CCMP, such as downregulation of the density of β receptors, impaired
β‐adrenergic signaling, alternations of calcium‐ion channels, and alternations in plasma
membrane fluidity in cardiomyocytes. In addition, the increased serum bile acids, cytokines,
and endotoxins have been shown to create negative effects on cardiomyocytes [9–12, 14, 22].
Figure 1. Cirrhotic cardiomyopathy pathogenesis.
Vasoconstrictor substances are high in the early stages of PHT, and vasodilator substances
gradually increase in advanced stages; the balance tips in favor of vasodilators and a receptor
insensitivity develops against vasoconstrictors [10–12, 19, 23–30]. As a result of these events,
arterial vasodilatation results and the severity of PHT increases [19, 23–30].
The splanchnic vasodilatation that develops in PHT is combined with a hyperkinetic systemic
circulation, low arterial tension, decreased peripheral resistance, and increased cardiac flow.
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Although total plasma volume increases, as a result of collection of blood in the splanchnic
area, effective blood capacity cannot be achieved, and central hypovolemia develops. After
these changes, activation of the sympathetic nervous system and renin‐aldosterone system
occurs; vasopressin release from the hypothalamus increases, which results in fluid and salt
retention [30–33].
The vasoconstrictor and vasodilator substances in the pathogenesis PHT become effective
together. The most important vasoconstrictor substances are norepinephrine, angiotensin II,
vasopressin, thromboxane (TX), and leukotrienes. The effects of these substances are related
with activation of the sympathetic nervous system and renin‐angiotensin‐aldosterone system.
Researches have shown that portal venous tension can be decreased using alpha‐adrenergic
antagonists (prazosin), beta‐adrenergic antagonists (propranolol), angiotensin‐II antagonists,
cyclooxygenase isoenzyme blockers, and TX antagonists. Results of these researches support
the pathogenesis [22, 29–34].
Endothelin (ET) can show vasoconstrictor or vasodilator effects according to the type. Endo‐
thelins are classified as ET‐1, ET‐2, and ET‐3 according to their region in the body. ET‐1 is mainly
found in endothelial cells, the kidney, and the brain and ET‐2 in the small intestine and kidney,
and ET‐3 is found in the blood. ET‐1 and ET‐2 create a vasoconstrictor effect, whereas ET‐3 has
a vasodilator effect. These two opposite effects are associated with the induction of nitric oxide
and prostacyclin release. The most potent vasoconstrictor substance in the body is ET‐1, and
it is reported that this substance is very effective in the development of PHT complications [22,
29–34].
Nitric oxide (NO) is another very potent substance in the pathogenesis of PHT. NO is synthe‐
sized from arginine by nitric oxide synthetase (NOS) and causes vasodilatation by increasing
cyclic guanosine monophosphate. NO initially increases to compensate against the elevated
vasoconstrictor agents in the early stage of PHT, but secondary systemic and splanchnic
vasodilatation develops because of excessive NO production. This event is a result of stimu‐
lation of NOS by cytokines such as TNF‐alpha, which increases in cirrhosis [22, 30–36].
The other important vasodilator substances in the pathogenesis of PHT are carbon monoxide
(CO), hydrogen sulfide (H2S), prostaglandins, glucagon, and endocannabinoids. CO formed
through the heme‐oxygenase system is a weaker vasodilator agent than NO, but it is important
for regulation of intrahepatic vascular tone. H2S is formed by intestinal microbiota and
increases the effects of other vasodilator substances and PHT severity [22, 30–36].
Prostaglandins are endogen vasodilators produced in the endothelium and are important for
hyperdynamic circulation. Prostacyclin is produced from the vascular endothelium. It leads
to vasodilatation, which increases the level of intracellular cyclic adenosine monophosphate
(c‐AMP) through the activation of adenylate cyclase. In recent studies, it was shown that
indomethacin, a prostacyclin inhibitor, decreased the hyperdynamic circulation and balanced
the vasoconstrictor effect [22, 30–36].
Glucagon is a hormone released from the pancreas. Glucagon levels increase as a result of low
hepatic clearance and stimulation of pancreatic alpha cells in patients with cirrhosis. Glucagon
also has the effect of reducing endogenous vasoconstrictor activity in addition to having a
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vasodilator effect. The use of somatostatin and synthetic glucagon analogs for PHT therapy
has been proposed in some studies; however, these agents may constitute a risk because they
can aggravate the splanchnic vasodilatation in advanced stages [22, 30–36].
Endocannabinoids such as anandamide are vasodilator substances that increase in PHT,
worsen hepatic microcirculation, and accelerate apoptosis. These substances act by stimulating
CB1 and CB2 receptors in the vascular endothelium. It has been reported that endogen
cannabinoids show a negative inotropic effect on myocardial contractions, and therefore these
substances are very important for the development of cirrhotic cardiomyopathy [39–41]. These
negative effects can be blocked by CB‐1 receptor antagonists (AM251) [22, 30–40].
4. Clinical finding and diagnosis
Cirrhotic cardiomyopathy (CCMP) represents a condition in which no real cardiac disease is
present but a functional cardiac abnormality exists. With time, CCMP progresses to the chronic
phase. In a resting state, there is no real disease, but with stress, the cardiac muscle does not
contract appropriately and and/or electrophysiologic abnormalities appear [10–12]. There is
no exact classification for CCMP and the criteria proposed by Moller et al. are still used
(Table 2). These data are taken from an adult studies, pediatric data are very limited [41–45].
The most important points from these criteria are (1) at rest, normal, or increased left ventric‐
ular contractibility; (2) abnormal systolic contraction or diastolic relaxation with pharmaco‐
logic, physiologic, or surgical stress; and (3) cardiac electrical abnormalities [10, 11].
Diagnosis of CCMP in children with cirrhosis is difficult, because invasive methods are life‐
threatening and noninvasive tests are unreliable for them. In recent years, a new article was
published in which CCMP criteria for children were reviewed [45]. According to this literature,
a prolonged QT interval on electrocardiography (ECG) is an important finding after all non‐
liver causes are excluded, and shows latent cardiomyopathy due to cirrhotic changes. If there
is the presence of echocardiographic abnormalities, this event is a manifest CCMP [45].
Cirrhotic cardiomyopathy is a latent disease in which there is no abnormality except under
stress conditions. In such patients, there is no cardiac disease till end‐stage disease. At end
stage, infrequent arrhythmias or cardiac insufficiency may be seen. If these findings exist in
an early cirrhotic stage, other causes of cardiomyopathy such as infections, metabolic disor‐
ders, endocrinopathies, ischemic or toxic causes, and genetic and systemic diseases should be
investigated [46].
Cirrhotic cardiomyopathy is more likely dilated cardiomyopathy where some stress factors
cause cardiac dysfunction. With stress, the clinical status of the patient deteriorates and
decompensation may exist. These stress factors are exercise, infection, positional changes,
feeding, paracentesis with high volumes, changes in intravascular volume, the use of vaso‐
constrictor drugs, transjugular intrahepatic portosystemic shunts (TIPS), or surgical proce‐
dures such as minor operations or liver transplantation [10–12]. Exercise tolerance in patients
with cirrhosis is abnormal due to cardiac function abnormalities, and this correlates with the
patient’s Child score [47].
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Systolic dysfunction criteria Supporting criteria
• Inadequate cardiac flow to pharmacologic agents,
exercise, blood volume changes
• Resting ejection fraction under 55 %
• Electrophysiologic abnormalities
• Abnormal chronotropic response
• Electromechanical uncoupling/dyssynchronism
• Prolonged QT intervals
• Expended left atrium
• Increased myocardial mass
• Increased BNP and pro‐BNP levels
• Increased troponin I levels
Diastolic dysfunction
• E/A ratio <1,0 (corrected according to age)
• Prolonged deceleration time
(>200 milliseconds)
• Prolonged isovolumetric relaxation time
(>80 milliseconds)
BNP, brain natriuretic peptide; E/A ratio, the ratio between the early (E) and late atrial (A) phases of ventricular
velocity
Table 2. Diagnostic criteria of cirrhotic cardiomyopathy.
There is a relationship between CCMP and hepatorenal syndrome (HRS), which has been
reported in many articles published in recent years, so patients with HRS are at more risk [5,
25, 48].
Cardiac functions in patients with liver cirrhosis are determined by physical examination,
ECG, and telecardiography besides of echocardiography. Cardiac functions such as systolic,
diastolic, and electromechanical functions should be evaluated in suspected CCMP. ECG is
sufficient for determining electrophysiologic function. Systolic and diastolic functions are
checked using M‐Mod, two‐ and three‐dimensional echocardiocardiography, and spectral and
tissue Doppler echocardiocardiography. Cardiac magnetic resonance imaging, radio nuclear
angiography, and myocardial perfusion techniques are more advanced methods. Many times,
for a diagnosis of CCMP, the findings on ECG and echocardiocardiography are enough.
Firstly, systolic function worsens in the late stage of CCMP. After then, the diastolic functions
gradually decay. Diastolic dysfunction is best shown with echocardiographic measurement of
the E/A ratio. Deceleration time (DT) and the isovolumetric relaxation time (IVRT) also are
used. The E/A ratio results from blood velocity from the left atrium to the left ventricle, the
velocity of which during early systole causes the E wave and the same flow causes the A wave
during late diastole.
The measurement of E and A waves is expressed as cm/sec and best is done from mitral valve
projection. A normal E/A ratio in healthy individuals until the age of 50 years is 1–2 cm/s, but
in older people, it decreases below 1 cm/s. An E/A ratio in healthy individuals aged less than
50 years below 1 cm/s shows diastolic dysfunction. However, the restrictive pattern can be
observed in advanced stages depending on the severity of the disorder in the patients with
CCMP; the E/A ratio may reverse in these cases and may be determined >2 [10, 11, 49]
(Figure 2).
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Figure 2. Diastolic dysfunction stages [49]. MAP, mean atrial pressure; NYHA, New York Heart Association; Ddf
stage, diastolic dysfunction stage.
Indicator Normal pattern  Abnormal relaxation (stage I) Pseudonormal pattern (stage II)  Restrictive pattern
(stages III–IV)
E/A >1 <1 1–2 ≥2
DT (msn) 160–210 >220 150–200 <150
IVGT (msn)  70–90 >95 60–95 <60
DT, deceleration time; E/A, transmitral early diastolic flow (E)/transmitral late diastolic flow (atrial) (A) ratio; IVGT,
isovolumetric relaxation time (msn).
Table 3. Echocardiographic stages of left ventricular diastolic dysfunction [49].
There are different stages in CCMP. Clinical findings differ according to stage (Table 3). The
E/A ratio worsens according to the severity of hepatic disease and it is worse in patients with
ascites than in patients with non‐ascites and normal persons. The E/A ratio improves after
paracentesis and this event supports that ascites is the negative effect on cardiac functions [50–
53]. There are no publications on these themes in children. There is no definitive normal value
for the E/A ratio in children, but in some publications, it is proposed to be between 1.7 and
2.5 cm/s.
Electrical conduction abnormalities and arrhythmias can be seen in the patients according to
severity of cirrhosis [8, 9] [54–58]. There are three types of electrophysiologic abnormalities
caused by cirrhosis: (1) prolonged QT on ECG, (2) inadequate response to chronotropic stress,
and (3) electromagnetic dyssynchronism [10, 11, 14]. The prolonged QT on ECG means a
corrected QT interval (QTc) is longer than 0.440 value [41, 54, 55]. Prolonged QT shows
abnormal myocardial repolarization as a sign of CCMP [10–12, 56–58]. QT prolongation
Cirrhotic Cardiomyopathy
http://dx.doi.org/10.5772/65318
265
proportionally increases with cirrhotic stage [56]. Prolonged QT on ECG is frequently seen in
patients with CCMP. The rate of determination of prolonged QT is 30–60 % in adults with
CCMP and in 18–45 % of pediatric patients [5, 41, 44, 56].
Actually, a prolonged QT interval may cause life‐threatening arrhythmias [55], but in many
patients with CCMP, despite a prolonged QT interval, no significant clinical problem and
arrhythmia are not observed. Cardiac arrhythmias in cirrhotic patients are frequently related
to vasopressin use. There is no evidence that a prolonged QT interval in patients with CCMP
causes life‐threatening arrhythmias. Probably, some compensatory mechanisms in cirrhotic
patients prevent the disturbances and the disease occurs latent until end stage.
5. Treatment
Treatment consists of preventing stress exposure in patients with CCMP; rest and oxygen
supplementation are important [10, 59]. There is no need for pharmacotherapy when there is
no cardiac insufficiency. Drugs have adverse effects and pharmacotherapy response is weak
in patients with CCMP. In recent years, aldosterone antagonists, cannabinoid receptor
antagonists, and spironolactone have been used, but only the effectiveness of beta‐blockers
has been proved [10, 35, 59]. Beta‐blockers can decrease QT wave duration [10, 32, 33].
Diagnosis of CCMP at an early stage is important. Early diagnosis and proper treatment with
cardioprotective agents are important for decreasing complications during and after liver
transplantation. There are no exact data on prognosis for liver transplantation in patients with
CCMP. Data from the past showed that CCMP worsens in the early period after liver trans‐
plantation, and later cardiac functions and cardiac electromechanical dysfunctions improve
gradually by supplying hemodynamic stabilization of the patient [10, 59–64]. Liver transplan‐
tation can be a definitive treatment for CCMP. New pharmacologic agents are needed to help
these patients because many patients do not have the chance to receive a transplant.
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